Made me laugh Blip-cu, even if hopelessly optimistic. There's many a slip betwixt mouse and human lip (or anywhere else for that matter). Here's hoping the clinical trial results are terrific and we find a suitable partner on reasonable terms to fund the long road to a vaccine. In the meantime I'm hoping the turnaround in CC production efficiency and revised strategy will help the company get on the road to being cash-positive (or at least a manageable cash-burn) in the medium term.
HSV-2 Vax Results, page-19
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.20 |
Change
-0.290(2.32%) |
Mkt cap ! $257.9M | |||
| Open | High | Low | Value | Volume |
| $12.49 | $12.50 | $11.80 | $396.0K | 32.70K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 923 | $11.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.20 | 1821 | 1 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |